ArticleBioprocess and biosystems engineering2026
Tailoring high-cell-density fed-batch fermentation strategies to produce Russell's viper venom-specific single-domain antibody in E. coli.
Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Attributes of camelid-derived single-domain antibodies (sdAbs), such as enhanced antigen specificity, improved solubility and stability, efficient tissue penetration, and superior biodistribution, make them preferable therapeutics for diverse applications, including the treatment of cancers, neurological disorders, infectious diseases, and intoxication. Limited availability and high cost of antivenoms necessitate the discovery of alternative neutralizers. This investigation presents a proof of concept for developing a cost-effective Escherichia coli-based platform to produce high yields of an sdAb specific to Russell's viper venom, denoted as 'FRV'. The gene encoding the FRV protein was cloned into the pET28a vector, and expression was evaluated in shake flasks using both complex and chemically defined media at various temperatures, achieving a maximum concentration of ~ 190 mg/L and a specific product yield (Y
Indexed as
Identifiers
42873278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.